Effective Treatment for Cystic Fibrosis with Rare Mutations
Author Information
Author(s): Sütering Tomke, Bode Sebastian F. N., Fischer Rainald, Fabricius Dorit
Primary Institution: Ulm University Medical Center
Hypothesis
Can Elexacaftor/Tezacaftor/Ivacaftor (ETI) effectively treat people with cystic fibrosis who have rare non-phe508del mutations?
Conclusion
ETI shows significant efficacy in improving lung function and quality of life in people with cystic fibrosis who have rare CFTR mutations.
Supporting Evidence
- FEV1 improved significantly after 3 and 6 months of ETI therapy.
- Sweat chloride levels decreased significantly, with four patients achieving levels below 60 mmol/L.
- Improvements in quality of life and medication satisfaction were noted.
- ENT symptoms significantly reduced after 6–8 months of ETI therapy.
Takeaway
This study found that a new medicine helped people with a rare type of cystic fibrosis breathe better and feel healthier over a year.
Methodology
This was a retrospective observational study evaluating six patients with cystic fibrosis and rare CFTR mutations undergoing off-label ETI therapy over 12 months.
Potential Biases
Potential observer and patient bias due to the retrospective nature of the study.
Limitations
The small sample size limits the generalizability of the findings.
Participant Demographics
Participants included 3 males and 3 females aged 6 to 66 years with various rare CFTR mutations.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website